In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...

Summit shared data from the HARMONi-2 study at the World Conference on Lung Cancer conference in San Diego, US.

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Keytruda's dominance as a mainstay in cancer immunotherapy isn’t threatened by an experimental Chinese drug, a top Merck ...

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly ...

Study results provide much-anticipated details to Summit’s claim earlier this year that its drug “decisively beat” Merck’s ...

The cost-effectiveness body recommended Keytruda in locally advanced or metastatic PD L1-positive non-small-cell lung cancer in adults who have had at least one chemotherapy, and targeted ...

Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage ...

Some patients with non-small cell lung cancer saw a 49% reduction in the risk of disease progression or death with ...

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...

We are hopeful this positive duration of response continues and, as seen in first line non-small cell lung cancer in the ...